Infraredx, an intravascular imaging company committed to advancing the diagnosis and management of coronary artery disease, today announced the enrollment of 1,000 patients in the Lipid-Rich Plaque Study. The LRP Study is a prospective, multi-center clinical trial designed to identify a correlation between lipid-rich plaques detected by Infraredx’s TVC Imaging SystemTM and the occurrence of a cardiac event within two years.
The first-in-class dual-modality intravascular imaging system integrates near-infrared spectroscopy (NIRS) with intravascular ultrasound (IVUS) technology, allowing clinicians the ability to assess vessel structure and plaque composition. The TVC Imaging System is FDA-approved to identify lipid-core plaques that may cause heart attacks.
Identification of such plaques would be a major step toward the development of percutaneous coronary intervention (PCI) as a means to prevent coronary events. Current PCI imaging technologies are limited in the information they can provide about non-flow limiting plaques that may be dangerous.
